Articles By Jonathan Kay, MD

hand stopping falling dominos

Toward Long-Term Prevention of Rheumatoid Arthritis: Are We Closer?

By Jonathan Kay, MD

As earlier diagnosis and treatment of rheumatoid arthritis (RA) have resulted in greatly improved clinical outcomes, the focus of current research has now shifted to preventing the development of RA altogether. At EULAR 2025, several oral presentations explored this objective, highlighting data from three key prevention trials: APIPRA, ARIAA, and TREAT EARLIER. Each trial targeted individuals considered to be “at-risk” for developing RA, investigating whether early immunomodulatory interventions could delay or prevent progression to classifiable RA.

Read Article
holding hands together support frail

Is Rheumatoid Arthritis Preventable?

By Jonathan Kay, MD

Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis. However, the "Holy Grail" remains the prevention of its development. During a clinical symposium at EULAR 2024 in Vienna, updates were presented on four prospective intervention trials conducted in patients experiencing joint pain without visible joint swelling.

Read Article
biosim.sign_.jpg

Adalimumab Biosimilars: Realizing the Promise of Market Competition

By Jonathan Kay, MD

Over four years after adalimumab biosimilars were first launched in the European Union and elsewhere, adalimumab biosimilars have finally become available in the United States. 

Read Article
guidelines.recommendations.jpg

New ACR RA Guidelines and Practice Changing Abstracts: RA Panel

By Jonathan Kay, MD

Dr. Jonathan Kay leads an international panel discussion on the new ACR RA guidelines and several practice-changing abstracts presented at the 2020 ACR meeting. Panelists include Dr. Kathryn Dao, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway and Dr. Sheila Reyes.

Read Article
Profile picture for user Jonathan Kay, MD
  • Jonathan Kay, MD

  • Jonathan Kay, MD, is Professor of Medicine and Population and Quantitative Health Sciences and holds the Timothy S. and Elaine L. Peterson Chair in Rheumatology at the University of Massachusetts Medical School in Worcester, where he directs Clinical Research in the Division of Rheumatology. His clinical appointment is as a Physician at UMass Memorial Medical Center. Dr. Kay’s clinical interests span the spectrum of rheumatic diseases, with special interest in rheumatoid arthritis, spondyloarthropathies, and other forms of inflammatory arthritis. Over the past three decades, his clinical research has focused on nephrogenic systemic fibrosis (formerly known as nephrogenic fibrosing dermopathy), beta2 -microglobulin amyloidosis, and other rheumatologic problems of patients with chronic kidney disease. He has been a principal investigator on over 60 clinical trials of novel therapies for rheumatoid arthritis, axial spondyloarthritis, gout, and osteoarthritis. Over the past decade, he has been involved in the development of biosimilars to treat rheumatic diseases. Dr. Kay lectures internationally and is the author of more than 240 publications and book chapters.

×